Sustanon

ACTIVE INGREDIENT

Each mL contains:

• Testosterone Propionate 30 mg
• Testosterone Phenylpropionate 60 mg
• Testosterone Isocaproate 60 mg
• Testosterone Decanoate 100 mg

DESCRIPTION

Sustanon 250 mg is a blend of four testosterone esters designed to provide both immediate and long-lasting effects following intramuscular administration. Each ester has a different rate of release, ensuring a sustained and consistent testosterone level over time. Sustanon is primarily used in testosterone replacement therapy (TRT) for males with conditions associated with primary or secondary hypogonadism.

PHARMACOLOGICAL PROPERTIES

Mechanism of Action: Testosterone, the active component of Sustanon 250 mg, is the primary male sex hormone, responsible for developing and maintaining male sexual characteristics and increasing muscle mass and bone density. The combination of four different testosterone esters ensures a rapid onset of action and sustained effect.

Pharmacokinetics:

• Absorption: The blend of testosterone esters is absorbed at varying rates. Testosterone Propionate acts quickly, while Phenylpropionate, Isocaproate, and Decanoate provide a longer release profile.
• Distribution: Testosterone is extensively bound to plasma proteins, including sex hormone-binding globulin (SHBG).
• Metabolism: Testosterone is metabolized primarily in the liver into two active metabolites: dihydrotestosterone (DHT) and estradiol.
• Excretion: Testosterone and its metabolites are excreted primarily via urine.

INDICATIONS

Sustanon 250 mg is indicated for:

1. Testosterone replacement therapy in male adults with conditions related to primary or secondary hypogonadism (congenital or acquired).
2. Treatment of delayed puberty in males.
3. Hormone therapy for transgender men (female-to-male).

DOSAGE AND ADMINISTRATION

Dosage: The dosage of Sustanon 250 mg should be individualized according to the patient’s clinical response and testosterone levels. Typical dosages range from 250 mg every 2 to 3 weeks, with the goal of maintaining normal testosterone levels.

• Hypogonadism in adult males: 250 mg intramuscularly every 3 weeks.
• Delayed puberty in males: Dosage should be individualized, typically 50–100 mg every 2–4 weeks, adjusted based on clinical response.

Testosterone levels should be monitored to ensure they remain within the target range.

Administration: Administer intramuscularly. Inject deeply into the gluteal muscle. Rotate injection sites to prevent local irritation and tissue damage. Do not inject intravenously.

CONTRAINDICATIONS

• Hypersensitivity to any testosterone esters or excipients.

• Known or suspected carcinoma of the prostate or breast in men.

• Pregnancy and breastfeeding (Pregnancy Category X).

• Severe hepatic, renal, or cardiac disease.

• Patients with a history of thromboembolism or cardiovascular disorders.

WARNINGS AND PRECAUTIONS

1. Cardiovascular Risks: Testosterone replacement therapy, including Sustanon 250 mg, may increase the risk of cardiovascular events such as heart attack, stroke, and thromboembolism. Use with caution in patients with cardiovascular conditions.

2. Prostate Health: Testosterone therapy may exacerbate benign prostatic hyperplasia (BPH) and increase the risk of prostate cancer in older men. Regular monitoring of prostate-specific antigen (PSA) levels and prostate health is recommended during treatment.

3. Hematological Effects: Testosterone can stimulate red blood cell production, leading to an increased risk of polycythemia. Hematocrit levels should be monitored regularly, especially in patients receiving long-term treatment.

4. Fluid Retention: Sustanon may cause fluid retention, which could worsen conditions like heart failure or kidney disease. Patients with a history of fluid retention should be monitored closely.

5. Hepatic Effects: Androgens have been associated with hepatotoxicity, including hepatic tumors and peliosis hepatis. Regular liver function tests are recommended during long-term therapy.

6. Misuse and Abuse: Testosterone and anabolic steroids, including Sustanon 250 mg, may be misused by athletes or individuals aiming to increase muscle mass. Abuse can lead to serious health consequences such as cardiovascular damage, liver damage, and psychiatric effects.

ADVERSE REACTIONS

Common adverse reactions:

• Local: Pain, irritation, or swelling at the injection site.
• Dermatological: Acne, oily skin, increased body or facial hair, scalp hair thinning.
• Endocrine: Gynecomastia, decreased sperm production, testicular atrophy.
• Cardiovascular: Hypertension, increased risk of thromboembolic events.
• Hematological: Increased hemoglobin and hematocrit (risk of polycythemia).
• Psychiatric: Mood swings, aggression, anxiety, or depression.

Rare but serious adverse effects:

• Hepatotoxicity (liver damage), especially with long-term or high-dose use.
• Serious cardiovascular events such as myocardial infarction or stroke.
• Prostate hypertrophy or cancer.

INTERACTIONS

1. Anticoagulants: Testosterone may enhance the anticoagulant effect of warfarin and other anticoagulants. Regular monitoring of INR and prothrombin time is recommended during co-administration.

2. Corticosteroids and ACTH: Concurrent use may increase the risk of fluid retention, especially in patients with pre-existing heart or kidney conditions.

3. Antidiabetic agents: Testosterone therapy may affect blood sugar levels, requiring adjustments to insulin or oral antidiabetic medications.

USE IN SPECIFIC POPULATIONS

Pregnancy and Lactation: Sustanon 250 mg is contraindicated in pregnant and breastfeeding women. It may cause fetal harm if administered to a pregnant woman.

Pediatric Use: In adolescents, testosterone therapy should be used with caution to avoid premature closure of epiphyses and to ensure monitoring of bone development and growth.

Geriatric Use: Elderly patients receiving testosterone therapy may have an increased risk of developing prostate hypertrophy or cancer. Prostate health should be monitored regularly.

OVERDOSAGE

Symptoms of testosterone overdose may include priapism (prolonged erections), excessive fluid retention, and polycythemia. In the event of overdose, discontinue treatment and provide supportive care. There is no specific antidote for testosterone overdose.

STORAGE

Store below 25°C (77°F). Protect from light. Do not refrigerate or freeze. Keep out of reach of children.

PACKAGING

Sustanon 250 mg is supplied in 10 mL vials containing 250 mg of testosterone ester blend.

MANUFACTURER

Oxydine Metabolics Switzerland

Oxydine.org
Hi@Oxydine.org